MSK Kids: Recent Research Advances for High-Risk Neuroblastoma | Memorial Sloan Kettering Cancer Center
Avoiding myeloablative therapy after Rapid COJEC intensive induction does not adversely affect survival in high-risk neuroblastoma.
This retrospective analysis shows that omitting myeloablative therapy (MAT) following Rapid COJEC induction chemotherapy does not compromise event‑free survival (EFS) or overall survival (OS) in children with high‑risk neuroblastoma.
Demonstrating that MAT can be safely avoided supports a treatment approach that reduces toxicity while preserving survival outcomes for high‑risk neuroblastoma patients.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study